sCT alone and combined with liraglutide treatment increases the number of cFos- activated neurons in the DVC of adult rats In an attempt to identify nuclei within the brain that may offer a complementary set of neural circuits that mediate, at least in part, the combined anorectic effects of amylin and GLP-1 pharmacotherapy, we focused our attention on those nuclei in the DVC given the wealth of literature showing the contribution of this structure to the intake suppressive effects of either amylin- or GLP-1-based monotherapy 6,7,8,10
While the FDA has acknowledged Ozempics role in reducing the risk of cardiovascular events and kidney disease, Zepbound is also approved for Obstructive Sleep Apnea (OSA) in obese individuals
V., Hindsberger, C., Robson, R
Once a closely guarded secret among celebrities and the ultra-wealthy, these drugs have become widely accessible in recent years, driving a surge in popularity among those looking to drop pounds
Comparative efficacy of GLP-1 RAs/SGLT-2 inhibitors in reducing cardiovascular events in type 2 diabetes according to baseline use of metformin: a systematic review and meta-analysis of randomized controlled trials
Key Takeaways: GLP-1 agonists, such as Ozempic and Wegovy, carry a black box warning due to an association with thyroid cancer, particularly in individuals with RET gene mutations